Tevogen Bio Holdings (G280) Stock Statistics & Valuation Metrics
Total Valuation
Tevogen Bio Holdings has a market cap or net worth of EUR 34.40M. The enterprise value is EUR 38.83M.
- Market Cap
- EUR 34.40M
- Enterprise Value
- EUR 38.83M
Share Statistics
Tevogen Bio Holdings has 6,511,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,511,540
- Owned by Insiders
- 71.78%
- Owned by Institutions
- 0.97%
Financial Efficiency
Tevogen Bio Holdings’s return on equity (ROE) is 3.19 and return on invested capital (ROIC) is 3698.66%.
- Return on Equity (ROE)
- 3.19
- Return on Assets (ROA)
- -5.99
- Return on Invested Capital (ROIC)
- 3698.66%
- Return on Capital Employed (ROCE)
- 9.73
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.46M
- Employee Count
- 18
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Tevogen Bio Holdings is -1.01. Tevogen Bio Holdings’s PEG ratio is -0.02.
- PE Ratio
- -1.01
- PS Ratio
- 0.00
- PB Ratio
- -2.54
- Price to FCF
- -2.11
- Price to Operating Cash Flow
- -1.95
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Tevogen Bio Holdings had revenue of 0 and earned -26.28M in profits. Earnings per share was -8.08.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -26.14M
- Pretax Income
- -26.28M
- Net Income
- -26.28M
- EBITDA
- -25.57M
- Earnings Per Share (EPS)
- -8.08
Cash Flow
In the last 12 months, operating cash flow was -11.57M and capital expenditures -64,426, giving a free cash flow of -11.63M billion.
- Operating Cash Flow
- -11.57M
- Free Cash Flow
- -11.63M
- Free Cash Flow per Share
- -3.04
Dividends & Yields
Tevogen Bio Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -47.35%
- Earnings Yield
- -95.66%
Stock Price Statistics
- Beta
- 1.11
- 52-Week Price Change
- -82.20%
- 50-Day Moving Average
- 6.57
- 200-Day Moving Average
- 7.98
- Relative Strength Index (RSI)
- 32.37
- Average Volume (3m)
- 20
Important Dates
Tevogen Bio Holdings upcoming earnings date is Nov 24, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 24, 2026
- Ex-Dividend Date
- ―
Financial Position
Tevogen Bio Holdings as a current ratio of 0.22, with Debt / Equity ratio of -37.66%
- Current Ratio
- 0.22
- Quick Ratio
- 0.22
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- -0.10
- Interest Coverage Ratio
- -133.63
Taxes
In the past 12 months, Tevogen Bio Holdings has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Tevogen Bio Holdings EV to EBITDA ratio is -1.27, with an EV/FCF ratio of -2.28.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.27
- EV to Free Cash Flow
- -2.28
- EV to Operating Cash Flow
- -2.29
Balance Sheet
Tevogen Bio Holdings has EUR 1.08M in cash and marketable securities with EUR 3.04M in debt, giving a net cash position of -EUR 1.96M billion.
- Cash & Marketable Securities
- EUR 1.08M
- Total Debt
- EUR 3.04M
- Net Cash
- -EUR 1.96M
- Net Cash Per Share
- -EUR 0.30
- Tangible Book Value Per Share
- -EUR 2.32
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Tevogen Bio Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 36.06%
Scores
- Smart Score
- 2
- AI Score
- ―
